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Genistein modulates the decreased drug accumulation in
non-P-glycoprotein mediated multidrug resistant tumour cells
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Lankelma & H.J. Broxterman
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Summary In tumour cells the pharmacological basis for multidrug resistance (MDR) often appears to be a
reduced cellular cytostatic drug accumulation caused by the drug efflux protein, P-glycoprotein (Pgp MDR), or
by other drug transporters (non-Pgp MDR). Here we report the reversal of the decreased daunorubicin (DNR)
accumulation in five non-Pgp MDR cell lines (GLC4/ADR, SW-1573/2R120, HT1080/DR4, MCF7/Mitox and
HL60/ADR) by genistein. Genistein inhibited the enhanced DNR efflux in the GLC4/ADR cells. In these cells
the decreased VP-16 accumulation was also reversed by genistein. Three other (iso)flavonoids biochanin A,
apigenin and quercetin also increased the DNR accumulation in the GLC4/ADR cells. In contrast to the
effects on non-Pgp MDR cells, 200 iLM genistein did not increase the reduced DNR accumulation in three Pgp
MDR cell lines (SW-1573/2R160, MCF7/DOX40 and KB8-5) or in the parental cell lines. In conclusion the
use of genistein provides a means to probe non-Pgp related drug accumulation defects.
In many tumour cell lines with acquired MDR, drug resis-
tance is associated with the overexpression of a plasma mem-
brane protein, P-glycoprotein (Pgp), the product of the mdrl
gene (Endicott & Ling, 1989). Pgp functions as an energy-
dependent drug efflux pump, which decreases free cellular
drug concentrations, thus rendering cells resistant to
cytotoxic agents (Broxterman & Pinedo, 1991). However, in
some cancers, such as lung and breast, the expression of Pgp
in general is low and/or heterogeneous (Lai et al., 1989; Linn
et al., 1992), implicating that other resistance mechanisms
contribute to clinical resistance.
A number ofdrug-selected cell lines has now been reported
to show the MDR phenotype (resistance to a wide range of
cytostatic agents with no common structure or target) but
without the overexpression of Pgp (so called non-Pgp MDR)
(McGrath et al., 1989, Kuiper et al., 1990; Coley et al., 1991;
Slovak et al., 1988; Ta.ylor et al., 1991). In some of these
non-Pgp MDR cell lines the expression of mdrl is even
decreased (Baas et al., 1990). Thus far at least two
mechanisms have been shown to be operative in drug resis-
tance in non-Pgp MDR cells. The first mechanism is a
decreased drug concentration at target due to a decreased
cellular accumulation of drugs (McGrath et al., 1989; Kuiper
et al., 1990; Coley et al., 1991; Slovak et al., 1988; Taylor et
al., 1991) and/or an altered distribution of drugs (Schuurhuis
et al., 1991; Takeda et al., 1991). We have previously shown
by using a digitonin based assay that the decrease in DNR
accumulation occurred against a concentration gradient in a
number of Pgp and non-Pgp MDR cell lines (Versantvoort et
al., 1992a). Furthermore in some non-Pgp MDR cell lines the
accumulation of drugs was shown to be decreased due to an
energy-dependent mechanism (Coley et al., 1991; Marquardt
et al., 1990; Versantvoort et al., 1992b). Therefore other drug
transporters than Pgp have to be present in those non-Pgp
MDR cells. The second mechanism that contributes to the
resistance in several non-Pgp MDR cells is an alteration in
topoisomerase II activity (Slovak et al., 1988; De Jong et al.,
1990).
In non-Pgp MDR cells the effects of Pgp resistance
modifiers such as verapamil and chloroquine usually are less
than in Pgp MDR cells (Schuurhuis et al., 1991; Cole et al.,
1989; Zijlstra et al., 1987). It is therefore of interest to search
for resistance modulators more effective and selective for
non-Pgp MDR, in order to be able to modulate non-Pgp
mediated MDR and to gain more insight into the properties
of the drug transporter(s) involved.
Recently, several reports have indicated that modulators of
protein kinase C (PKC) activities were able to modulate Pgp
MDR (Yu et al., 1991; Bates et al., 1992; Chambers et al.,
1992). Stimulation of Pgp phosphorylation by PKC
activators PMA (TPA) was correlated with a decrease of
drug accumulation (Bates et al., 1992; Chambers et al., 1992;
Fine et al., 1988), while inhibition ofPgp phosphorylation by
staurosporine, a protein kinase inhibitor, caused an increase
of drug accumulation by inhibition of the drug efflux
(Chambers et al., 1992; Ma et al., 1991). Furthermore, in Pgp
expressing BC-19 cells transfected with PKCa, Pgp was more
phosphorylated and this resulted in more resistant cells with
a further decreased vinblastine accumulation compared to the
cells without PKCa transfection (Yu et al., 1991). Moreover,
PKC seemed to be involved in drug resistance independent of
Pgp, since exposure of drug-sensitive cell lines to phorbol
ester induced a drug-resistant phenotype (Takeda et al., 1991;
Fine et al., 1988). Interestingly, in one such a cell line
selected for resistance to TPA (K562/TPA) genistein, a
tyrosine kinase inhibitor, was able to alter the subcellular
doxorubicin distribution (Takeda et al., 1992). These reports
suggest that protein kinases might be involved in Pgp as well
as non-Pgp MDR.
In an effort to gain more insight in the regulation of the
drug transport mechanisms in non-Pgp MDR cells, we
examined the effects of the protein kinase inhibitors, stauro-
sporine and genistein, on cellular drug accumulation and
doxorubicin distribution in two non-Pgp MDR lung car-
cinoma cells lines, SW-1573/2R120 and GLC4/ADR. For
comparison several Pgp MDR and other non-Pgp MDR cell
lines, all cell lines characterised by a decreased drug
accumulation, were studied. In this report we show that
genistein is a modulator of drug accumulation in non-Pgp
MDR cells but not in Pgp MDR cells.
Materials and methods
Chemicals
Daunorubicin hydrochloride was obtained from Sigma
Chemical Company (St Louis, MO) and etoposide (VP-16)
from Bristol-Myers Squibb Co. (Weesp, The Netherlands).
Genistein, biochanin A, apigenin, quercetin, staurosporine,
phorbol-12-myristate-13-acetate (PMA/TPA) and verapamil
were purchased from Sigma Chemical Company (St. Louis,
MO). [G-3H] daunorubicin (sp. act. 1.6 Ci/mmol) was
obtained from Du Pont de Neumours (Germany), [32P]ortho-
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phosphate (act. 10 mCi ml-') from Amersham (Amersham,
UK) and [G-3H] VP-16 (sp. act. 1 Ci/mmol) from Moravek
Biochemicals (Brea, CA).
As measured by trypan blue exclusion, the cells remained
viable during the drug accumulation studies with genistein
and staurosporine.
Cells
The human non-small cell lung carincoma cell line SW-1573
and the doxorubicin resistant sublines SW-1573/2R120
(2R120, non-Pgp MDR) and SW-1573/2R160 (2R160, Pgp
MDR) have been described elsewhere (Kuiper et al., 1990).
The human breast cancer cell line MCF7 and the non-Pgp
MCF7/Mitox and the Pgp MCF7/DOX sublines were
obtained from Dr W. Dalton (Taylor et al., 1991). The
human epidermoid carcinoma cell line KB3-1 and its Pgp
MDR subline KB8-5 were obtained from Dr I. Roninson
(KB3-1) or through ATCC, Rockville, MD (KB8-5). The
human fibrosarcoma cell line HT1080 and its doxorubicin-
selected non-Pgp MDR subline HT1O8O/DR4 were provided
by Dr M Slovak (Slovak et al., 1988). All cell lines men-
tioned were cultured in monolayer in Nunc flasks (Roskilde,
Denmark) in Dulbecco's modified Eagle's medium (DMEM,
Flow, Irvine, UK) supplemented with 7.5% heat-inactivated
foetal calf serum (GIBCO, Paisley, UK). The human small
cell lung carcinoma cell line GLC4 and its doxorubicin-
resistant subline GLC4/ADR have been characterised before
(Zijlstra et al., 1987; De Jong et al., 1990). The human acute
myeloblastic leukaemia cell line HL60 and its non-Pgp MDR
subline HL60/ADR were obtained from Dr M. Center
(McGrath et al., 1989). The GLC4 and HL60 cell lines were
grown as floating cells in RPMI medium (Flow Labs., Irvine,
Scotland) with 10% foetal calf serum. The resistant cells were
cultured in the presence of selecting drug until 2-10 days
before experiments (except HL6O/ADR cells which were cul-
tured without drug). All cell lines were free from mycoplasma
as tested regularly with the Mycoplasma T.C. rapid detection
system with a 3H-labelled DNA probe from Gen-Probe Inc.
(San Diego, CA).
For growth inhibition experiments, cells were plated in
96-well plate (2000 cells/well) and after 24h exposed con-
tinuously with varying concentrations genistein. Cells were
then grown for 5 days. The cells were stained with MTT, and
the absorption was measured as previously reported (Kuiper
et al., 1990).
Phosphorylation ofP-glycoprotein
Cells were incubated in 6-well plates with 0.05-0.2mCi of
[32P]orthophosphoric acid in 1 ml of phosphate-free growth
medium with 2% foetal calf serum for 4 h. PMA or stauro-
sporine were added during the last 30 min of incubation.
Cells were then washed with ice-cold PBS, harvested by
scraping and homogenised in phosphate buffer containing
1% NP-40, 10mM NaF and 1 mM PMSF. P-glycoprotein
was immunoprecipitated with monoclonal antibody C-219
(Centocor, Inc., Malvern, PA) as described (Scheper et al.,
1993).
Cellular drug accumulation
The steady-state cellular accumulation of [3H]daunorubicin
and [3H]VP-16 was measured as described previously (Brox-
terman et al., 1988). Briefly, cells were incubated in growth
medium without sodium bicarbonate, but with 10% foetal
calf serum. DNAseI (0.025%) was included to prevent DNR
accumulation in any non-viable cells. The assay was initiated
by addition of the radiolabelled drug in the presence ofeither
the modulator of interest or the solvent alone. After 60 min,
the cells were rapidly washed twice with ice-cold phosphate
buffered saline.
For drug efflux, cells were incubated for 60 min with the
radiolabelled drug. After one wash with ice-cold phosphate
buffered saline, cells were resuspended in pre-warmed
medium. At the indicated time points the efflux was stopped
by another wash with ice-cold phosphate buffered saline.
Radioactivity was determined by liquid scintillation counting.
Intracellular distribution ofdoxorubicin
Measurement of subcellular doxorubicin distribution was
performed as described previously (Schuurhuis et al., 1989,
1991). Cells were allowed to adhere on tissue culture petri
dishes (Costar, Cambridge, MA) for 24 h. Floating cells were
allowed to adhere on Falcon dishes for 15 min in serum free
medium at 4°C. Cells were incubated in growth medium for
1.5 h with 8 or 32tiM doxorubicin at 37°C. After a rapid
wash with phosphate buffer saline, 10-30 cells were recorded
for each treatment using laser scan microscopy. Fluorescence
of doxorubicin in the nucleus and the fluorescence in the
cytoplasm were quantifed using digital image analysis as
described (Schuurhuis et al., 1989; De Lange et al., 1992).
Results
Effects ofPMA and staurosporine on DNR accumulation in
MDR cells
The effects of the protein kinase modulators PMA and
staurosporine on DNR accumulation were examined in the
non-Pgp MDR lung carcinoma cell lines, 2R120 and GLC4/
ADR, and compared with the Pgp expressing subline 2R160.
Figure la shows that in the 2R160 subline coincubation with
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Figure 1 Effects of PMA and staurosporine on DNR accumula-
tion and Pgp phosphorylation. a, 2R160 cells were incubated for
60 min with 0.5tLM 3H-DNR alone (L ) or with 20 nM PMA
( _ ), with various staurosporine concentrations 10 nM ( 1S ),
l0OnM ( ), 1ILM ( M ) or 20 liM digitonin ( M, mean of
two experiments). Data are expressed as mean ± s.d. of four
experiments done in triplicate. b, Parental SW-1573 and 2R160
cells labelled with 32P-orthophosphate were treated for the last
30 min with 20 nM PMA or staurosporine with concentrations as
indicated. The cells were lysed, Pgp was immunoprecipitated with
moab C219 and samples were analysed by 7.5% SDS gel electro-
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the PKC activator PMA decreased DNR accumulation with
about 50%, whereas staurosporine, a protein kinase
inhibitor, greatly enhanced the DNR accumulation in a con-
centration dependent manner. One JAM staurosporine in-
creased the DNR accumulation maximally, since the effect
was the same as the increase in DNR accumulation in res-
ponse to circumvention of the plasma membrane barrier with
digitonin. Under the conditions the maximal DNR binding
capacity of the cells at a given extracellular DNR concentra-
tion is measured (Versantvoort et al., 1992a).
In order to correlate the effects of PMA and staurosporine
on DNR accumulation with Pgp phosphorylation, the effect
of these compounds on 32[P]orthophosphate incorporation
into Pgp in intact 2R160 cells was measured. Exposure of
2R160 cells to PMA led to an increase of Pgp phosphoryla-
tion level, while exposure to staurosporine caused a
concentration-dependent decrease of phosphorylation of Pgp
(Figure lb). Blocking active drug transport by addition of
10 mm sodium azide and 25 mg ml-l deoxyglucose (5-fold
excess glucose) also resulted in a decrease of Pgp phos-
phorylation. Thus, the effects of modulation of PKC activity
in the Pgp expressing 2R160 MDR subline were consistent
with other reports (Chambers et al., 1992; Ma et al., 1991).
Therefore, we could compare the effects of PMA and
staurosporine on the DNR accumulation in the non-Pgp
MDR cells with the 2R160 cells.
In Figure 2 the effects of PMA and staurosporine on the
DNR accumulation in wild-type and non-Pgp MDR cells are
shown. PMA caused a small decrease in DNR accumulation
in the 2R120 but not in the GLC4/ADR non-Pgp MDR
cells. One JAM staurosporine, which had a maximal effect on
the DNR accumulation in the Pgp MDR 2R160 cells, in-
creased the DNR accumulation to a small, not significant
extent in the non-Pgp MDR cells. Incubation with lower
concentrations of staurosporine, which are still active in the
Pgp MDR cells, had no effects on DNR accumulation in the
non-Pgp MDR cells (not shown). Thus, whereas PMA and
staurosporine greatly modulated Pgp phosphorylation with a
concomitant modulation of its drug transport activity, no or
small effects of these compounds on DNR transport were
seen in these two non-Pgp MDR cells.
Effects ofgenistein on drug accumulation in non-Pgp and Pgp
MDR cells
Next we examined the effects of a member of the protein-
tyrosine kinase inhibitors i.e. genistein on DNR accumula-
tion. In Figure 3 the dose-response curve of the effects of
genistein on DNR accumulation in GLC4 cells is shown.
Genistein had no significant effect on the DNR accumulation
in the parental GLC4 cells but caused a dose-dependent
increase of the DNR accumulation in the resistant GLC4/
ADR cells. 200 JAM genistein was used for most further
experiments since this concentration could be obtained with
< 1% DMSO final concentrations.
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Figure 2 Effects of PMA and staurosporine on DNR accumula-
tion in non-Pgp MDR cells and 2R160 Pgp MDR cells. Cells
were exposed to 0.5 JLM 3H-DNR alone ( = ) or in presence of
20 nM PMA ( ) or staurosporine ( ). Error bar, s.d.
of at least three independent experiments.
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Figure 3 Dose-response curve of genistein. GLC4 (0) and the
resistant GLC4/ADR (A) cells were incubated for 60min with
0.5tAM 3H-DNR in presence of varying concentrations genistein.
Each point is the mean of 2-4 independent experiments.
Table I Genistein effect on DNR and VP-16 accumulation in GLC4
and SW-1573 cells
Daunorubicin VP-16
% of control % of control
200 JM genistein 8JM verapamil 200 iM genistein
GLC4 103 ± 17 (8) 106 (2) 107 ± 18 (3)
GLC4/ADR 313 65 (8)0 119 (2) 739 310 (3)a
SW-1573 108 26 (4) 104 (3) n.d.
2R120 161 ± 28 (4)a 134 (2) n.d.
2R160 67± 32 (4) 736 (3)a n.d.
aData of genistein and verapamil vs control accumulation are
significantly different, P<0.02 according to Student's paired t-test;
n.d., not determined.
Cells were incubated for 60 min with 0.51AM 3H-DNR or 10JIM
3H-VP-16 in the presence of 200JIM genistein, 8 lAM verapamil or
vehicle alone. Data are presented as percentage of control;
mean ± s.d., number of experiments in parentheses; each experiment
performed in triplicate.
As shown in Table I, 200JAM genistein enhanced the DNR
accumulation also in the non-Pgp MDR 2R120 cells, but was
without effect either in the parent SW-1573 cells or Pgp
expressing 2R160 cells. Verapamil increased the DNR
accumulation in 2R160 cells to more than 700% when 8 JLM
and completely (t 1,500%) when 64 JLM was used. In the
non-Pgp 2R120 and GLC4/ADR cells verapamil was less
effective than in Pgp MDR cells in modulation of the
decreased DNR accumulation; an increase to 120-130%
with 8 JAM verapamil but at a higher concentration of
verapamil (64 lAM) the DNR accumulation was significantly
enhanced (1.9-fold and 2.1-fold in the 2R120 and GLC4/
ADR cells, respectively). In the GLC4/ADR cells the
decreased accumulation of another MDR drug, VP-16, could
be reversed completely by 200 JM genistein.
We have shown previously that the accumulation of DNR
in GLC4/ADR cells is decreased merely due to an enhanced
energy-dependent efflux (Versantvoort et al., 1992b).
Therefore we now studied the effects of genistein on drug
efflux. The enhanced efflux of DNR from the GLC4/ADR
cells was inhibited partly with 200 JM genistein and com-
pletely with 50011M genistein (Figure 4), which is in accor-
dance with the effects on DNR accumulation (Figure 3).
Genistein had no effect on the efflux of DNR from the
parental GLC4 cells (Figure 4), showing that the passive
transport of DNR is not affected by 200 AM genistein.
In order to determine the specificity of the genistein effects
for non-Pgp MDR cells, we examined the effects of genistein
on DNR accumulation in several Pgp (2R160, KB8-5 and
MCF7/DOX40) and non-Pgp (GLC4/ADR, 2R120, HT1080/
DR4, MCF7/Mitox and HL60/ADR) MDR cells (Figure 5).942 C.H.M. VERSANTVOORT et al.
Table II Intracellular doxorubicin distribution
Control
+ DMSO Genistein Control Verapamil
GLC4 3.67±0.30 (2) 3.59 ±0.60 (2) 3.88 3.88 (1)
GLC4/ADR 0.88 ± 0.24 (3) 2.36 ±0.23a (3) 0.93 ± 0.21 (2) 2.62 ±0.45a (2)
SW-1573 2.07 ± 0.26 (2) 1.97 ±0.65 (2) 1.96 ± 0.33 (2) 1.94 ±0.19 (2)
2R120 1.40 ± 0.11 (5) 1.59 ±0.15a (5) 1.56 ± 0.21 (5) 1.62 ±0.19 (5)
2R160 0.25 ± 0.02 (2) 0.24 ±0.02 (2) 0.28 ± 0.04 (2) 1.26 +0.25a (2)
aSignificantly different compared to control; P<0.01, Student's paired t-test.
Cells were incubated for 1.5 h with 8-32 tLM doxorubicin with or without 200 tLM genistein or
32AM verapamil. Doxorubicin distribution is presented as Nuclear fluorescence divided by
Cytoplasmic fluorescence (N/C ratio). Data are mean + s.d., number of experiments in
parentheses, in each experiment 10-30 cells were measured.
We compared these results with the Pgp resistance modifier
verapamil. Genistein or verapamil increased the DNR
accumulation not more than 20% in any of the parental cell
lines (not significant). In all the five non-Pgp MDR cell lines,
200pM genistein stimulated the DNR accumulation. Whereas
8tLM verapamil increased the DNR accumulation in both
Pgp MDR and (most) non-Pgp MDR cells, 200ILM genistein
increased the accumulation only in the non-Pgp MDR cells.
Effect ofgenistein on subcellular doxorubicin distribution
Many non-Pgp as well as Pgp MDR cells show an altered
subcellular distribution of anthracyclines compared to the
sensitive cells (Schuurhuis et al., 1989, 1991; Gervasoni et al.,
1991); the ratio of nuclear to cytoplasmic doxorubicin
fluorescence (N/C ratio) is lower in the resistant cells. We
have shown previously that verapamil did not change the
subcellular distribution of doxorubicin in non-Pgp MDR
2R120 cells in contrast to the increase of the N/C ratio's in
the Pgp expressing SW-1573 sublines (Schuurhuis et al.,
1991). In order to know whether genistein was able to reverse
not only the decreased drug accumulation in non-Pgp MDR
cells but could also alter the drug distribution, we examined
the effects of genistein on the subcellular distribution of
doxorubicin.
In Table II the cellular doxorubicin distribution is reflected
as the N/C ratio. Firstly, the N/C ratio is lower in the MDR
cell lines compared to their parental cell lines (shown in
Figure 6a and 6b). Secondly, in the non-Pgp MDR GLC4/
ADR cells, the N/C ratio increased in response to exposure
to genistein illustrated in Figure 6b and c. Thirty-twoylM
verapamil also increased the N/C ratio in the GLC4/ADR
cells (Figure 6d). In the non-Pgp MDR 2R120 cells the N/C
ratio increased to a small extent in response to exposure to
genistein or verapamil. In these cells genistein increased the
N/C ratio in all the five independent experiments. The N/C
ratio increased in the Pgp MDR 2R160 cells only when using
verapamil but not with genistein and in the parental cell lines
the N/C ratio was not affected by either verapamil or
genistein.
Cytoxocity ofgenistein
We have shown that genistein is able to reverse the decreased
drug accumulation in non-Pgp MDR tumour cells. In order
to know whether genistein could be used as a resistance
modifier, the cytotoxicity of genistein was measured. In Table
III it is shown that genistein is about equally toxic to the
parental and the resistant cells. However, the concentrations
of genistein used in the drug accumulation studies were too
toxic to use for continuous exposure in drug cytotoxicity
experiments.
Comparative effects ofgenistein and structurally related
compounds on the DNR accumulation in GLC4 cells
In order to gain insight into the mechanism of action of
genistein on drug accumulation, effects of other isoflavonoids
and flavonoids on DNR accumulation were examined (Table
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Figure 4 Efflux of DNR from GLC4 cells in presence of
genistein. GLC4 (0,@) and GLC4/ADR (A,A,V) cells were
loaded for 60 min with 0.5 LM 3H-DNR in the presence of 200 yiM
genistein. Retention of DNR was measured after suspending the
cells in DNR-free medium alone (04,) or in presence of 200t4M
genistein (@,A) or in one experiment with addition of 500 gM
genistein (V). Error bar, s.d. of three independent experiments.
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Figure 5 Effect ofgenistein on DNR accumulation in Pgp MDR
and non-Pgp MDR cell lines. Cells were incubated for 60 min
with 0.5tLM 3H-DNR with addition of 200lIM genistein ( _ ) or
8JiM verapamil ( M ). Results are expressed as modifier/
control x 100%, mean ± s.d. of 2-8 experiments. The DNR
accumulation in the resistant cells was compared to the parental
cells was as follows: GLC4/ADR: 19 ± 8%, SW-1573/2R120:
30 ± 9%, HT1080/DR4: 24± 10%, HL60/ADR: 27 + 6%,
MCF7/Mitox: 75 ± 23%, SW-1573/2R160: 5 ± 5%, MCF7/
DOX40: 26 ± 4% and KB8-5: 26 ± 6%. #Statistically different
(P < 0.05) compared to control accumulation (Student's paired
t-test).
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Figure 6 Changes in intracellular doxorubicin distribution due
to exposure to genistein and verapamil. The procedure followed
is described in 'Materials and methods'. GLC4: a, 1.5-h incuba-
tion with 8 JM doxorubicin. GLC4/ADR cells 1.5-h incubation
with: b, 32 jM doxorubicin alone; c, 32JM doxorubicin in
presence of 200gAM genistein; d, 32gM doxorubicin in presence of
32 JAM verapamil.
Table III Growth inhibitory effect of genistein
IC50 in JAM
GLC4 18 8
GLC4/ADR 16 7
SW-1573 20± 10
2R120 41 ± 27
2R160 39± 36
Data are IC50 values of three experiments each performed in
quadruplicate.
Table IV Effects of genistein and structurally related compounds on
DNR accumulation
GLC4 GLC4/ADR
Cell line pmol % pmol %
modulator DNR/I06 cells DNR/I06 cells
Control 140± 15 100 21 ± 3 100
Genistein 150± 11 107 73 ± 13 354
Biochanin A 238 27 172 235 ± 11 1257
Apigenin 112 4 82 95± 4 493
Quercetin 99 ± 7 72 51 ± 9 254
Cells were incubated for 60 min with 0.5 JM 3H-DNR in the
presence of 200 JM modulator or 0.5% DMSO in the control
samples. Values represent mean ± s.d. of at least two experiments
each performed in triplicate.
IV). The structures of these compounds are depicted in
Figure 7. These compounds were less effective than genistein
in inhibition of tyrosine kinases (Akiyama et al., 1987).
The isoflavonoid biochanin A increased the DNR
accumulation in the parent GLC4 as well as in the resistant
GLC4/ADR cells; the increase was much more pronounced
in the resistant cells than in the sensitive cells (12-fold vs
1.5-fold). The flavonoids apigenin and quercetin increased the
DNR accumulation in the GLC4/ADR cells, while a small
decrease was measured in the GLC4 cells. From the com-
pounds tested, only biochanin A significantly enhanced the
DNR accumulation in the Pgp MDR 2R160 cells (not
shown).
It was checked whether the effects of the (iso)flavonoids on
the parental GLC4 and GLC4/ADR cells were due to
changes in intracellular pH, since DNR accumulation is
dependent on the pH (Skovsgaard & Nissen, 1982; Versant-
voort et al., 1992a,b). Therefore, intracellular pH was
measured using the pH sensitive, fluorescent dye BCECF
(Versantvoort et al., 1992b). Genistein had no effect on the
intracellular pH in the parental and resistant GLC4 cells.
Biochanin A, however, lowered the intracellular pH 0.25-0.3
in both the parent and resistant GLC4 cells. A lower intracel-
lular pH will result in a higher intracellular DNR accumula-
tion, since only the neutral form of DNR is passively trans-
ported over the plasma membrane. Thus the lowered intra-
cellular pH could explain the increase of DNR accumulation
by biochanin A in the GLC4 cells, and in part the large
increase of DNR accumulation in the GLC4/ADR cells as
calculated according to the Henderson-Hasselbach equation
(Skovsgaard & Nissen, 1982). Changes in intracellular pH
due to exposure to apigenin and quercetin could not be
determined reliably, because of interference of these com-
pounds with the fluorescence of BCECF.
Discussion
Overexpression of Pgp has been well established as the cause
of the MDR phenotype in many in vitro selected drug resis-
tant cell lines. In many human cancers Pgp/mdrl has been
demonstrated using monoclonal antibodies or gene probes
(Chan et al., 1990; Noonan et al., 1990; Bourhis et al., 1989).
Only in a few studies, however, the level of Pgp expression in
human tumours was correlated with their resistant
phenotype. Nooter et al. (1990), showed that the mdrl
mRNA expression correlated with a cyclosporin-A-induced
increase in cellular DNR accumulation in fresh human
leukemia cells. Interestingly, indications for the presence of
the other drug transporters were provided since in some
samples without detectable mdrl expression a cyclosporin-A-
induced increase in cellular DNR accumulation was
measured.
However, agents affecting the activity of Pgp may or may
not affect other MDR mechanisms (Schuurhuis et al., 1991;
Cole et al., 1989; Zijlstra et al., 1987). We here investigated
the effect of several different classes of protein kinase
inhibitors for their potential activity as reverters of decreased
DNR accumulation in Pgp and non-Pgp MDR tumour cells.
The results presented here show that in two phenotypically
rather similar MDR mechanisms, Pgp and non-Pgp MDR,
resistance modulators do not act similarly; verapamil is a
modulator for Pgp MDR cells and for non-Pgp MDR cells
(sometimes less effective), whereas genistein increased the
DNR accumulation only in the five non-Pgp MDR cells.
Genistein is, to our knowledge, the first compound shown to
enhance the decreased drug accumulation in non-Pgp MDR
cells without affecting Pgp MDR cells.
The basis for this difference in modulation spectrum is not
known. However, the fact that verapamil exerts its effects at
lower concentrations in Pgp MDR cells than in several non-
Pgp MDR cells, might indicate that the drug transporter(s) in
non-Pgp MDR cells have different drug binding and/or sub-
strate specificities compared to Pgp. Alternatively, the
activity of the transporters in non-Pgp MDR cells might be
affected differently at the level of phosphorylation by protein
kinases (Figure 2). Thus functional assays for the presence of
MDR cells in human cancer will allow a better interpretation
of the results of clinical trials aimed to overcome MDR with
resistance modifiers. Genistein might be used in functional
drug accumulation assays to probe non-Pgp MDR in cancer
cells.
Recently, in the non-Pgp MDR lung cancer cell line, H69/
AR, a potential drug transporter has been cloned, the Multi-944 C.H.M. VERSANTVOORT et al.
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Figure 7 Chemical structures of the compounds investigated. Isoflavonoids: genistein a; biochanin A c. Flavanoids: apigenin b;
quercetin d.
drug Resistance associated Protein (MRP), belonging to the
superfamily of the so called ABC-proteins (Cole et al., 1992).
Overexpression of mRNA of 7.8-8.2 kb was associated with
resistance in these cells. The MRP gene has now been shown
to be overexpressed in several (HT1080/DR4 and GLC4/
ADR, Slovak et al., 1993; Zaman et al., 1993) but not in all
(SW-1573/lR50 and SW-1573/2R120, Zaman et al., 1993)
non-Pgp MDR cells. Previously, an Mr 190,000, ATP-binding
protein has been suggested to be involved in drug transport
in the resistant leukemic HL60/ADR cells (McGrath et al.,
1989). Preliminary results with photoaffinity labelling with
8-azido-ATP revealed that also in the resistant GLC4/ADR
cells an ATP-binding protein of about 190 kD is overexp-
ressed (not shown). Western blotting with the polyclonal
antisera ASP-14 and CRAI (prepared by Dr M. Center and
Dr P. Twentyman), derived against a synthetic peptide cor-
responding to an amino acid sequence of Pgp, revealed the
overexpression of a 190 kD protein in HL60/ADR, COR/
L23-R and GLC4/ADR non-Pgp MDR cell lines (Marquardt
et al., 1990; Barrand et al., 1993; Versantvoort et al., 1992c).
Preliminary results with antibodies derived against synthetic
peptides encoded by the MRP gene, revealed that the 190 kD
protein is the product of the MRP gene (Cole, 1993).
Another protein of 110 kD is also overexpressed in most but
not all of the non-Pgp MDR cell lines (Scheper et al., 1993).
In normal tissue this 110 kD protein is like Pgp highly exp-
ressed in tissue with secretory-excretory functions (Scheper et
al., 1993). Further investigation of these proteins will reveal
their involvement in drug transport in MDR cells not
mediated by Pgp.
Genistein is potent and specific inhibitor of tyrosine kinase
activity, as measured by inhibition ofautophosphorylation of
EGF receptor in membranes of A431 cells (Akiyama et al.,
1987). Furthermore genistein (<25 JLM) has been shown to
affect cell proliferation and differentiation either via its ability
to interact with protein tyrosine kinases, phosphatidylinositol
kinases or via inhibition of DNA topoisomerase II (Dean et
al., 1989; Honma et al., 1992; Yoneda et al., 1991). A
common sequence at or near the ATP-binding site may
account for the inhibition of this diverse group of enzymes
(Markovits et al., 1989; Akiyama et al., 1987). Among the
flavonoids and isoflavonoids tested here, quercetin is known
to inhibit not only tyrosine kinases but also PKC, phos-
phorylase kinase and 5'-nucleotidase, whereas apigenin and
biochanin A exhibit only low activity for inhibition of EGF
receptor phosphorylation (Akiyama et al., 1987). These
analogues were shown to be inactive in inhibition of DNA
topoisomerase II activity (Markovits et al., 1989). In contrast
with those effects specific for genistein, also quercetin,
apigenin and biochanin A caused an increase in DNR
accumulation in the non-Pgp MDR GLC4/ADR cells (Table
IV). This suggests that other mechanisms than inhibition of a
tyrosine kinase might affect the drug transport in non-Pgp
MDR cells, although a role for a tyrosine kinase with a
different sensitivity profile and low affinity for genistein can-
not be excluded.
One might suggest that genistein binds directly to the drug
transporter(s) in the non-Pgp MDR cells. The non-Pgp
MDR cells, however, lacked cross-resistance to genistein
(Table III), suggesting that genistein is not effluxed itself
(also suggesting that inhibition of topoisomerase II was not
the major determinant of cell-kill in these cells, Markovits et
al., 1989). However, lack of cross-resistance in Pgp MDR
cells to resistance modifier verapamil had been demonstrated
(Schuurhuis et al., 1990), although verapamil is thought to
modulate the drug transport in Pgp MDR cells by binding to
and by being itself pumped out of the cells by Pgp (Yusa &
Tsuruo, 1989; Qian & Beck, 1990). Therefore, further studies
with genistein should be done to reveal whether such a
mechanism is the basis of the effect of genistein on drug
transport in non-Pgp MDR cells. Since the cytotoxic effects
of genistein might be due to the inhibition of protein tyrosine
kinases, it is worthwhile to search for less toxic analogues,
which might be able to reverse the resistance in non-Pgp
MDR tumour cells.
This work was supported by the Netherlands Cancer Foundation
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